Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seres Therapeutics

- PMLiVE

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada

- PMLiVE

eureKARE to use $60m financing to bolster next-generation European biotech companies

New company is focused on financing biotech companies and new ventures in Europe working on the microbiome and synthetic biology

- PMLiVE

Seres’ microbiome-based therapy hits the mark in phase 3

Drug reduced C.difficile infection recurrence

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

Finch’s microbiota drug for C. diff gets FDA breakthrough status

Boost for firm as it races rivals in microbiome space

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

All the latest from the frontlines of healthcare

Roche Basel Switzerland

Roche digs out soil drug discovery deal with Lodo

Lodo is raiding the rich microbial world of soil for potential new drugs

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

Microbiome specialist Rebiotix chalks up C. diff trial success

Drug therapy can prevent recurrent infections

- PMLiVE

Nestlé Health Science invests $145m in food allergy biotech

Aimmune Therapeutics' lead product is a phase III peanut allergy treatment

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links